[2]Reig M,Forner A,Rimola J,et al.BCLC strategy for prognosis prediction and treatment recommendation:the 2022 update.J Hepatol.2022;76(3):681–693. [3]Park JW,Chen M,Colombo M,et al.Global patterns of hepatocellula...
2．Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358-380.3．Liu M, Tseng TC, Jun DW, et al. Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hep...
[2] van Santen DK,Sacks-Davis R,Stewart A,et al.Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019[J].EClinical...
参考文献 上下滑动查看 1.Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. 2.Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of ...
(MβCD) treatment, CD147 fluorescence on the cell membrane weakened, internalized, and diffused into the cytoplasm (Fig.2A). Here, the expression of CD147-marked intracellular segments on the cell membrane was detected by flow cytometry (FC) in Huh7 (P = 0.0459,P = 0.0354,P ...
[15]Marcellin P, Gane EJ, Flisiak R, et al. Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials.Hepatology.2014;60...
Radical resection is still the first treatment for early stage HCC patients. However, the early recurrence rate after radical resection affects the prognosis. Therefore, it is very important to understand the risk factors and predictors of early postoperative recurrence in advance, and conduct timely ...
and those with a large body habitus that limits sufficient acoustic penetration. This becomes relevant when considering the population in the United States which may not be represented by the study population of the aforementioned prospective Chinese study. Basing U.S. guidelines on results of the ...
2.Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358-380. 3.Liu M, Tseng TC, Jun DW, et al. Transition rates to cirrhosis and liver canc...
[32]HuB, YuM, MaX, et al. IFNalpha potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment[J]. Cancer Discov, 2022, 12(7):1718-1741. DOI: 10.1158/2159-8290.CD-...